Loading...
OTCM
AWHL
Market cap4mUSD
Jun 10, Last price  
0.13USD
Name

Aspira Women's Health Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.51
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.61%
Rev. gr., 5y
15.14%
Revenues
9m
+0.31%
27,246,00018,215,00044,000124,00001,175,0001,923,0002,094,0002,566,0002,521,0002,177,0002,642,0003,121,0003,053,0004,538,0004,651,0006,812,0008,184,0009,154,0009,182,000
Net income
-13m
L-21.55%
-35,433,000-22,066,000-21,282,000-18,330,000-22,048,000-19,034,000-17,790,000-7,146,000-8,819,000-19,209,000-19,115,000-14,968,000-10,497,000-11,371,000-14,845,000-17,630,000-31,710,000-21,575,000-16,690,000-13,094,000
CFO
-12m
L-23.79%
-22,897,000-20,439,000-20,268,000-15,440,000-3,114,000-20,935,000-15,581,000-10,398,000-8,224,000-16,808,000-18,365,000-13,963,000-8,129,000-9,367,000-12,966,000-14,734,000-27,395,000-32,185,000-15,894,000-12,113,000
Earnings
Aug 11, 2025

Profile

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
URL
https://aspirawh.com/
IPO date
Sep 29, 2000
Employees
85
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,182
0.31%
9,154
11.85%
8,184
20.14%
Cost of revenue
25,460
28,006
40,949
Unusual Expense (Income)
NOPBT
(16,278)
(18,852)
(32,765)
NOPBT Margin
Operating Taxes
(5,595)
Tax Rate
NOPAT
(16,278)
(18,852)
(27,170)
Net income
(13,094)
-21.55%
(16,690)
-22.64%
(21,575)
-31.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,377
4,187
7,688
BB yield
Debt
Debt current
243
995
1,244
Long-term debt
3,781
2,443
2,936
Deferred revenue
Other long-term liabilities
60
1,651
2,280
Net debt
2,255
841
(9,377)
Cash flow
Cash from operating activities
(12,113)
(15,894)
(32,185)
CAPEX
(37)
(24)
(232)
Cash from investing activities
(37)
(24)
(232)
Cash from financing activities
11,064
5,216
7,427
FCF
(15,806)
(18,895)
(27,010)
Balance
Cash
1,769
2,597
13,306
Long term investments
251
Excess cash
1,310
2,139
13,148
Stockholders' equity
(531,380)
(518,292)
(498,773)
Invested Capital
531,646
520,430
511,615
ROIC
ROCE
EV
Common stock shares outstanding
14,135
9,233
518
Price
Market cap
EV
EBITDA
(16,186)
(18,653)
(32,501)
EV/EBITDA
Interest
17
Interest/NOPBT